Vertex Pharmaceuticals (VRTX) Total Liabilities (2009 - 2026)

Vertex Pharmaceuticals' Total Liabilities history runs 18 years deep, the most recent figure standing at $7.1 billion for Q1 2026.

• On a quarterly basis, Total Liabilities rose 11.56% year-over-year to $7.1 billion in Q1 2026; TTM through Mar 2026 was $7.1 billion, a 11.56% increase from a year earlier, with the FY2025 full-year figure at $7.0 billion, up 13.94% from the prior year.
• Total Liabilities advanced to $7.1 billion in Q1 2026 per VRTX's latest filing, from $7.0 billion in the prior quarter.
• Across five years, Total Liabilities topped out at $7.5 billion in Q3 2025 and bottomed at $3.3 billion in Q1 2022.
• The 5-year median for Total Liabilities is $5.4 billion (2024), against an average of $5.5 billion.
• Across the five-year window, Total Liabilities climbed 6.84% in 2022 and jumped 41.79% in 2023, its largest moves.
• Year by year, Total Liabilities stood at $4.2 billion in 2022, then gained by 21.51% to $5.1 billion in 2023, then advanced by 18.91% to $6.1 billion in 2024, then advanced by 13.94% to $7.0 billion in 2025, then increased by 2.08% to $7.1 billion in 2026.
• Per Business Quant, the three latest VRTX Total Liabilities figures stand at $7.1 billion (Q1 2026), $7.0 billion (Q4 2025), and $7.5 billion (Q3 2025).